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Abstract
In contrast to other haematological malignancies, targeted immunotherapy has not entered standard treatment regimens
for de novo or relapsed multiple myeloma (MM) yet. While a number of IgG-formatted monoclonal antibodies are currently
being evaluated in clinical trials in MM, our study aimed to investigate whether the fully human IgM monoclonal antibody
PAT-SM6 that targets a tumour-specific variant of the heat shock protein GRP78 might be an attractive candidate for future
immunotherapeutic approaches. We here show that GRP78 is stably and consistently expressed on the surface on tumour
cells from patients with de novo, but also relapsed MM and that binding of PAT-SM6 to MM cells can specifically exert
cytotoxic effects on malignant plasma cells, whereas non-malignant cells are not targeted. We demonstrate that the
induction of apoptosis and, to a lesser extent, complement dependent cytotoxicity is the main mode of action of PAT-SM6,
whereas antibody dependent cellular cytotoxicity does not appear to contribute to the cytotoxic properties of this antibody.
Given the favourable safety profile of PAT-SM6 in monkeys, but also in a recent phase I trial in patients with malignant
melanoma, our results form the basis for a planned phase I study in patients with relapsed MM.
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Introduction
Multiple myeloma (MM) is a malignant disorder characterized
by clonal expansion of plasma cells in the bone marrow leading
clinically to anaemia, bone destruction, monoclonal gammopathy,
renal failure, hypercalcemia and increased susceptibility to
infections [1]. Although treatment options for MM patients have
improved over the past decade, MM remains largely incurable.
Particularly, relapsed and refractory MM is associated with
survival times of less than 30 months [2] resulting in a clear need
to develop novel therapeutic approaches across all lines of MM
therapy.
Targeted immunotherapy using monoclonal antibodies (mAbs)
has substantially improved the treatment of lymphoid malignan-
cies resulting in better initial disease control and corresponding
higher rate of remissions in many lymphoma patients [3]. In
contrast, antibody-based immunotherapy has not been approved
for standard treatment in MM [4] despite several clinical trials
testing IgG formatted antibodies. At present, novel candidates
including elotuzumab or daratumumab targeting the plasma cell
associated antigens CD319 and CD38, respectively, [5,6] are
being explored in phase I/II and III trials, but their success
remains to be established [7].
In general, molecules that are selectively overexpressed on the
cell surface of neoplastic cells and that play an important role in
cell growth or survival represent attractive targets for immuno-
therapy. Binding of therapeutically effective mAbs exerts cytotoxic
effects by directly inducing apoptosis or via complement-depen-
dent cytotoxicity (CDC) or the activation of cytotoxic immune
effector functions such as antibody-dependent cellular cytotoxicity
(ADCC) [8].
The fully human IgM mAb PAT-SM6 was initially isolated
from a patient with gastric cancer and was described to be part of
the natural immunity. In a previous study, we could demonstrate
that PAT-SM6 targets a tumour specific variant of the heat shock
protein GRP78 (BIP, HSPA5) [9]. GRP78 is known to be an
endoplasmic reticulum-related protein, but it is also expressed on
the cell surface of various epithelial cancer cells [10] and increased
expression levels of GRP78 in cancer cells have been correlated
with an adverse prognosis and drug resistance [11]. In addition,
we and others reported that PAT-SM6 also binds to oxidized low-
density lipoprotein (LDL). The simultaneous binding of oxidized
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LDL and cell-surface GRP78 induces internalisation of oxidised
LDL in malignant cells causing intracellular deposition of
cholesterol and triglyceride esters which in turn triggers the cells
to undergo apoptosis [12,13].
GRP78 expression data in human tumours, in vitro cell-based
assays, and in vivo human tumour xenograft studies suggest that
PAT-SM6 may be an effective anti-tumour agent in several
indications. The safety of this antibody treatment was recently
demonstrated in cynomolgus monkeys, but also in a phase I trial
evaluating safety, pharmacokinetics, immunogenicity, pharmaco-
dynamics and anti-tumour activity of PAT-SM6 in patients with
recurrent in-transit cutaneous melanoma (ACTRN
12610000733077).
In this study, we investigate the target expression profile of the
IgM antibody PAT-SM6 in primary MM cells and demonstrate
anti-tumour effects and their potential underlying mechanisms.
Materials and Methods
Ethics Statement
This study was approved by the Ethics Committee of the
Medical Faculty of the University of Würzburg (reference no. 44/
10) and IRB-approved written informed consent was obtained
from all participants.
Cell Culture
Human multiple myeloma (MM) cell lines INA-6, NCI H929,
MM1.S, OPM-2 and U266 were obtained from the German
Collection of Microorganisms and Cell Cultures (Braunschweig,
Germany), ATCC (Manassas, VA), or kindly provided by M.
Gramatzki (Kiel) [14] and maintained as previously described
[15]. Primary CD138+ MM cells from patients were obtained
using positive selection with CD138 microbeads (Miltenyi Biotech,
Bergisch Gladbach, Germany).
Antibodies
Anti-GRP78 antibody PAT-SM6 (fully human IgM) was
produced as outlined elsewhere [16] and provided by Patrys
Ltd. (Melbourne, Australia). Anti-GRP78 control mAb (rabbit
IgG, ET-21) was obtained from Sigma-Aldrich (St. Louis, MO).
The anti-CD20 antibody Rituximab (Roche) was used as
complement activating control antibody in CDC studies. Chrom-
Pure IgM was used as isotype control (Dianova, Germany).
PAT-SM6 Immunostaining on Bone Marrow Paraffin
Sections
Immunohistochemistry (IHC) with PAT-SM6 antibody or
control antibodies on bone marrow paraffin sections and cytospin
preparations was performed as previously described [17].
Flow Cytometry
Direct and indirect immunofluorescence flow cytometric
analysis was performed using a FACScan with CellQuest Pro
acquisition software (Beckman Coulter, Miami, FL). The expres-
sion of GRP78 on MM cells was assessed using anti-GRP78 IgG
(rabbit), as well as PAT-SM6 followed by fluorescein isothiocya-
nate (FITC)-conjugated secondary antibodies (Abcam or Dako).
Isotype controls (human IgM or rabbit IgG) were used for the
assessment of unspecific binding. The expression of CD138 was
analysed using anti-CD138-FITC mAb (Beckman Coulter).
The recruitment of C1q to OPM-2 cells facilitated by PAT-
SM6 was assessed by incubating cells with C1q (Quidel A400) and
PAT-SM6 or IgM isotype control (ChromPure) respectively. Cells
were stained using murine anti C1q mAb (Quidel A401) and anti
murine IgG conjugated to flourescein (DAKO). Overlay was
shown against unspecific C1q binding with IgM isotype control.
ELISA (Enzyme-linked Immunosorbent Assay)
96-well plates (Corning CostarH 3590, NY) were used for the
ELISA experiments. Coating was performed overnight at 4uC
with reagents diluted in 0.05 M sodium bicarbonate buffer, pH 9.
Samples were prepared as triplicates. Following coating all steps
were performed at room temperature. Between incubation steps
plates were washed 3 times with PBS/0.05% Tween 20, pH 7.4.
Blocking was performed with PBS/0.05% Tween 20/2%BSA,
pH 7.4 for 2 h. Tetramethylbenzidine (TMB) substrate was added
and the reaction was stopped with 3 M H2SO4. Absorbance was
measured at 450 nm using an ELISA reader.
For complement factor q1 (C1q) binding analysis, plates were
coated with antibody concentrations ranging from 0.5 mg/ml to
20 mg/ml using triplicates. After blocking plates were incubated
with human C1q (Quidel A400) 2 mg/ml for 2 h followed by
sheep anti human C1q-HRP (Abcam, ab 46191) for 2 h.
For IgM binding to recombinant GRP78, plates were coated
with GRP78 (produced in HEK293 cells, kindly provided by
Patrys GmbH) ranging from 0.1 to 10 mg/ml. After blocking
plates were incubated with natural IgM antibodies 2 mg/ml for
3 h followed by incubation with anti-human IgM-HRP (Dako)
diluted 3:5,000 for 2 h.
For competition studies, all wells were coated with 10 mg/ml
GRP78. Increasing amounts of GRP78 or control protein with the
same molecular weight were added to a solution of PAT-SM6 IgM
(2 mg/ml in PBS/0.05% Tween 20/0.2%BSA, pH 7.4). After
incubation for 3 h anti-human IgM-HRP (Dako) diluted 3:5,000
was added and incubated for 2 h.
Cytotoxicity Assays
MM cell lines (26105 cells/ml) or CD138-purified patient MM
cells were incubated with PAT-SM6 or human isotype control
IgM (0–400 mg/mL) in 96-well plates for 48 h (primary MM cells)
or 72 h (MM cell lines). MM cell lines were tested in RPMI
containing 1% FCS. Primary MM cells were tested in RPMI
containing 10% FCS and IL-6 (2,5 ng/mL).
Cell death was determined by FACS analysis using the guava
via count kit (Millipore Merck, Darmstadt, Germany). Propidium
iodide and LDS-75 double positive cells were set as dead cells.
Annexin and 7-AAD positive cells were determined using the
Nexin Kit (Milipore Merck) according to manufacturer’s protocol.
Caspase 3 Activation Assay using PAT-SM6 in the MM1.S
Cell Line
Determination of caspase 3 activation was performed using the
AC-DEVD-AMC protease assay (BD Biosciences Pharmingen) as
previously described by Mashima et al. [18]. Briefly, 26105 cells
were incubated with PAT-SM6 or controls (isotype as negative
control or staurophorin as positive control) in a 6-well plate in a
total volume of 2 mL/well. After incubation for 3 h, 6 h, 24 or
48 h, respectively, cells were harvested, centrifuged at 13,000 rpm
and stored at 220uC. Cell pellets were lysed (200 mM Tris
pH 7.5, 2 M NaCl, 20 mM EDTA, 0.2% Triton X 100 lysis
buffer), centrifuged, and supernatants were transferred to a 96-well
plate. Reaction buffer (50 mM Pipes pH 7.4, 10 mM EDTA,
0.5% Chaps) was added to the wells with or without caspase 3
inhibitor (AG Scientific, San Diego, CA) and incubated overnight
at room temperature. RFU counts were determined using a
fluorescent reader.
IgM Antibody Induced Cell Death in MM
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CDC Assays
50 ml of cell suspension (10,000 cells per well) was added into
each well of a 96-well plate followed by 50 ml of antibody dilution
(starting from 0.01 mg/ml up to 400 mg/mL total concentration/
well diluted in RPMI containing 1% FCS) of PAT-SM6,
rituximab or controls. After incubation for 15 min, 50 mL
complement (normal human complement, Quidel, San Diego,
CA) was added. The plates were incubated for 2 hours at 37uC
with 5% CO2. After incubation the plates were centrifuged at
2,000 rpm for 5 min and supernatant was discarded. 30 ml of PBS
buffer and 270 ml of a prepared solution of propidium iodide and
LDS75 (Via Count Reagent, Millipore) were added to each well.
After incubation for 15 minutes in the dark, cell viability was
examined by micro-capillary flow cytometry (Guava PCM96
platform) and the ratio of live to dead cells was calculated for each
well by counting 2,000 events per well using Cytosoft software. All
experiments were repeated at least three times.
CDC activity was assessed by alamar blue as described
previously [19]. Briefly, 50 ml cell suspension (10,000 cells) was
transferred into each well followed by 50 ml dilution of antibody
PAT-SM6 or rituximab (starting from 1 mg/ml up to 400 mg/mL
total concentration/well) and isotype control (Chrompure IgM
400 mg/mL total concentration/well). To set a control for 100%
lysis a Triton-X100 solution (2.5 Vol%) was used. After incubation
at 37uC and 5% CO2 for 15 min, 50 ml complement was added to
each well, followed by 15 ml of alamar blue solution (10 ml/100 ml
cell suspension according to manufacturer) after 2 h incubation.
All dilutions were performed in RPMI containing 10% FCS.
Plates were incubated for 16 hours at 37uC and 5% CO2 and
subsequently analysed using a fluorescence reader. All experiments
were repeated at least three times.
ADCC Assay
CFSE labelled MM cell line OPM-2 was incubated with PAT-
SM6 (20 mg/mL or 50 mg/mL) or unrelated polyclonal IgM
(ChromPure, Dianova, Germany). Peripheral blood mononuclear
cells (PBMC) from healthy donors in an effector to target ratio of
25:1 or 50:1 in RPMI supplemented with 1% human serum were
added. After incubation of 4 or 24 h cells were stained with 7-
AAD for cell death determination and analysed by FACS. 7-
AAD/CFSE double positive cells were set as MM cells killed by
ADCC.
Antibody Induced NK Cell Activation Assessed by CD69
Expression
OPM-2 MM cells were incubated with PAT-SM6 or unrelated
polyclonal IgM (ChromPure, Dianova, Germany) for 15 min on
ice followed by centrifugation. Cells were transferred into a 24-well
plate (flat bottom) and co-incubated with PBMC from a healthy
donor in an effector to target ratio of 10:1 for 0 and 20 hours. NK
cell activation was determined using CD56, CD3 and CD69
fluorescent conjugated antibodies (BD, Germany) analysed by
FACS.
Statistical Analysis
In vitro experiments were repeated in triplicates, and the results
are reported as mean with standard error. Statistical significance of
differences observed in experimental versus control condition was
determined using the Student t-test or Wilkoxen sum rank test.
The minimal level of significance was P,0.05. The statistical
analysis was performed using GraphPad prism 5.
Results
PAT-SM6 Specifically Binds to Primary MM Cells
A panel of 10 monoclonal patient-derived IgM antibodies was
screened for their binding capacity to MM cells. All selected IgM
antibodies had shown tumour reactivity with a broader panel of
different carcinomas in previous studies [17]. The human IgM
antibody PAT-SM6 showed strongest staining by immunohisto-
chemistry (IHC) on cytospin preparations and displayed binding to
all tested MM cell lines (INA-6, NCI H929, MM1.S, OPM-2 and
U266) in FACS analysis (Fig. 1A). Therefore, PAT-SM6 was
selected for further analysis in primary human MM cells. Here,
PAT-SM6 specifically reacted with CD138-purified cells from
MM patients displaying 100% binding by FACS (Fig. 1A).
Furthermore, a homogenous membrane staining could be
observed in cytospin preparations, whereas CD138+ normal
plasma cells which were obtained from healthy volunteers showed
no PAT-SM6 binding, indicating a tumour cell specific binding
(Figure S1).
PAT-SM6 Binds to MM Cells in Bone Marrow Infiltrates in
All Cases
To generate representative data on the expression pattern of the
PAT-SM6 target structure in MM patients, immunohistochemical
staining in bone marrow biopsies was performed. In total, 24
samples were evaluated, including 11 MM patients at primary
diagnosis, 9 MM patients in first or later relapse (Table 1) and 4
samples from healthy donors. PAT-SM6 specifically bound to
MM cells in all 20 samples with a homogenous staining pattern of
80–100% of tumour cells (mean: 92%), indicating that its target
structure is stably expressed in MM throughout various stages of
the disease. A statistically significant difference in the percentage of
PAT-SM6 positively stained cells MM cells at primary diagnosis
vs. relapse could be observed (87% vs. 97%, p= 0.01, Table 1). In
8 of 20 samples, staining was limited to MM cells and did not show
any background reaction (Fig. 1B). In 12 samples very minor
background staining of less than 4% of nucleated cells was
observed that affected mainly myeloid progenitors. The four
healthy controls showed no PAT-SM6 binding reaction (repre-
sentative example shown in Figure 1B).
GRP78 Target Confirmation by ELISA,
Immunohistochemistry and FACS
We have previously shown that PAT-SM6 binds to a tumour-
specific isoform of GRP78, a member of the HSP70 family, as well
as to oxidized LDL [9,17]. Binding of PAT-SM6 to GRP78 and
oxidized LDL induces a tumour cell specific apoptotic process,
called lipoptosis [12]. Given the broad reactivity pattern of PAT-
SM6 we first investigated whether GRP78 is also the target
structure of this antibody on MM cells.
In ELISA binding studies, PAT-SM6 bound to recombinant
GRP78 in a dose dependent manner, whereas other unrelated
natural monoclonal IgM antibodies showed no reaction (Fig. 2A).
Findings were further validated in a competitive ELISA assay, in
which unbound GRP78 reduced binding of PAT-SM6 on a
GRP78 coated plate. A control protein with similar molecular
weight showed no effect. Thus, GRP78 is the target structure of
PAT-SM6 (Fig. 2B).
We next analysed the expression pattern of GRP78 in MM cell
lines and primary MM cells by FACS and immunohistochemistry
(IHC) using a rabbit anti-GRP78 IgG antibody. GRP78 was
expressed in all MM cell lines and primary MM cells tested. FACS
analysis revealed the target to be expressed on the plasma
membrane of the cells (Fig. 2C). IHC staining of bone marrow
IgM Antibody Induced Cell Death in MM
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Figure 1. PAT-SM6 specifically binds to MM cell lines and primary human MM samples. A, INA-6, NCI H929, MM1.S, OPM-2 and U266 MM
cell lines or CD138-purified patient MM cells were stained with PAT-SM6 (5 mg/mL, open histogram) or isotype control (gray histogram) followed by
IgM Antibody Induced Cell Death in MM
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sections indicated that MM cells stained positive for wild-type
GRP78, and that the staining pattern correlated with the pattern
displayed by PAT-SM6 (Fig. 2D). However, in contrast to PAT-
SM6, the rabbit anti-GRP78 IgG antibody reacted with non-
malignant cells as well. These findings provide additional evidence
that PAT-SM6 targets a tumour specific variant of GRP78 [9].
Taken together, the PAT-SM6 specific GRP78 variant is widely
expressed on the cell surface of MM cells, but not on healthy cells.
PAT-SM6 Mediates Cytotoxicity to MM Cells by Induction
of Apoptosis and Complement Activation
We previously demonstrated that PAT-SM6 induces apoptosis
after cell surface binding to GRP78 followed by internalization
into tumour cells [13]. To elucidate the ability of PAT-SM6 to
induce apoptosis in MM cells as well, MM cell lines and primary
MM cells were analysed by a propidium iodide/LDS75 based
FACS assay after treatment with PAT-SM6. MM1.S, OPM-2,
INA-6 and U266 cells displayed a dose dependent cell death when
incubated with PAT-SM6. At the highest concentration, PAT-
SM6 significantly increased the percentage of dead cells (median
range: 33–74.3%, Fig. 3A). Interestingly, U266 cells showed the
lowest antibody induced cytotoxic effect, in line with only modest
binding of PAT-SM6 to these cells in FACS analysis (Fig. 1A).
We next sought to validate the apoptotic effect of PAT-SM6 in
CD138-purified primary MM cells that were freshly obtained from
MM patients (n = 11) and cultivated in the presence of IL-6. PAT-
SM6 showed an induction of apoptosis in MM cells (mean: 58.2%;
median range: 19.2–94.6%, Fig. 3B). Of note, samples from
patients at initial diagnosis of MM (n= 8) and samples from
relapsed patients (n = 3) showed no significant difference (p= 0.7)
with mean apoptotic rates of 56.5% and 62.7%, respectively. We
conclude that PAT-SM6 exerts apoptotic effects in MM cells from
patients with de novo MM as well as in cells from patients with
several relapses.
fluorescein isothiocyanate (FITC)-conjugated secondary antibodies and assessed by flow cytometry. Both, cell lines as well as primary MM cells
displayed specific PAT-SM6 binding. B, Immunohistochemistry with PAT-SM6, CD138-positive control antibody or isotype on bone marrow biopsies
of MM patients. PAT-SM6 specifically stained MM cells with a homogenous binding pattern. In samples without MM infiltration no specific binding
was detected. Images were captured using a Leica DM BL microscope, the Leica ICC HD digital camera and the Leica LAS EZ V2.1.0 software.
doi:10.1371/journal.pone.0063414.g001
Table 1. Immunohistochemical analysis of the PAT-SM6 target expression pattern in bone marrow biopsies of MM patients.
Primary Diagnosis
Pat. Nr. MM Infiltration (CD138+) SM-6 stained CD138+ MM cells SM-6 stained cells other than myeloma
1 60% 90% myelopoiesis (5%)
2 25–30% 100% myelopoiesis (5%)
3 50–70% 80–90% myelopoiesis (5%)
4 40% 90% myelopoiesis (10%)
5 20–30% 80–90% myelopoiesis (5%)
6 30–40% 80% myelopoiesis (5%)
7 80–90% 80% none
8 70% 100% none
9 70–80% 80–90% none
10 60–70% 90% myelopoiesis (10%)






Pat. Nr. MM Infiltration (CD138+) PAT-SM6 stained CD138+ MM cells SM-6 stained cells other than myeloma
1 70% 80% myelopoiesis (5%)
2 30% 100% none
3 20% 90% none
4 70–80% 100% none
5 40–50% 100% none
6 25–30% 100% myelopoiesis (10%)
7 70% 100% myelopoiesis (5%)
8 50% 100% myelopoiesis (5%)
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Figure 2. Target validation, PAT-SM6 reacts with cell surface expressed GRP78. A, Sandwich ELISA with recombinant GRP78 and PAT-SM6.
Plates were coated with GRP78, blocked and incubated with PAT-SM6 or other natural IgM antibodies as controls followed by incubation with anti-
human IgM-HRP. PAT-SM6 showed binding to recombinant GRP78. B, Competitive ELISA: Plates were coated with GRP78 and increasing amounts of
GRP78 or control protein were added to a solution of PAT-SM6 followed by anti-human IgM-HRP. Unbound GRP78 reduced binding of PAT-SM6 on a
GRP78 coated plate. C, Surface expression GRP78 (black histogram) in MM cell lines is shown using an anti GRP78 IgG (rabbit) antibody. D, GRP78
expression in bone marrow biopsies was assessed by immunohistochemistry with anti GRP78 IgG, PAT-SM6 or positive control CD138. Primary MM
cells were positive for GRP78 and the staining pattern correlates with the pattern displayed by PAT-SM6. In contrast to PAT-SM6, anti-GRP78 IgG also
reacted with non-malignant cells. Images were captured using a Leica DM BL microscope, the Leica ICC HD digital camera and the Leica LAS EZ V2.1.0
software.
doi:10.1371/journal.pone.0063414.g002
IgM Antibody Induced Cell Death in MM
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In contrast, PBMCs isolated from blood of healthy donors
showed no cytotoxicity when treated with PAT-SM6 (Fig. 3B)
confirming the tumour specific cell death induced by PAT-SM6.
Cytotoxicity induced by PAT-SM6 was also observed in MM
cell lines by AnnexinV/7-AAD staining and an increased number
of AnnexinV/7-AAD double stained cells in primary MM cells
(Fig. 3C). Finally, induction of apoptosis was proven by a caspase 3
activation assay in MM1.S cells, indicating antibody mediated
apoptosis as the putative mode of action (Fig. 3D).
Since we had observed a minor background staining of PAT-
SM6 in myeloid progenitor cells in some bone marrow sections by
immunohistochemistry (Table 1), we wished to evaluate the
specificity in more detail. We thus isolated CD33-positive myeloid
progenitor cells from the bone marrow of a MM patient and
performed binding and cytotoxicity studies as described above.
Figure 3. PAT-SM6 mediates cytotoxicity to patient MM cells and MM cell lines by induction of apoptosis. A, MM cell lines were
incubated with various concentrations of PAT-SM6 or control (unrelated IgM at highest concentration) for 72 h. Cell death was determined by FACS
(Propidium iodide/LDS75 double positive cells). B, CD138-purified primary MM cells at primary diagnosis (n = 8, dots) or relapse (n = 3, rectangle) were
incubated for 48 h with PAT-SM6 or isotype in media containing IL-6 and 10% FCS. Dead cells were determined by FACS analysis (Propidium iodide/
LDS75 double positive cells). As control, PBMCs from healthy volunteers were treated under the same conditions. In contrast to controls PAT-SM6
significantly induced programmed cell death. C, MM1.S cells were incubated with PAT-SM6 or controls (staurophorin as positive control) for 72 h.
AnnexinV and 7AAD positive cells were assessed by flow cytometry. Percentage of 7-AAD/Annexin V double positive cells, Isotype: 14%, PAT-
SM6:79% and positive control: 76%. D, MM1.S cells were incubated with PAT-SM6 or controls (staurophorin or isotype) for 6 h and caspase 3
activation was measured using the AC-DEVD-AMC protease assay. E, Bone marrow cells from a MM patient were CD33-purified to obtain myeloid
progenitors and stimulated with PAT-SM6 or controls. No specific binding and subsequently no specific cytotoxicity was observed. F, Cells from the
same patient as in E were CD138-isolated and incubated with PAT-SM6 (200 mg/mL) for 24 h. Specific PAT-SM6 binding and killing was observed.
doi:10.1371/journal.pone.0063414.g003
IgM Antibody Induced Cell Death in MM
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PAT-SM6 neither showed reactivity with CD33-positive cells nor
induction of any specific cytotoxic effect (Fig. 3E) suggesting an
artificial background staining in immunohistochemical analyses. In
contrast, CD138-positive MM cells from the same patient showed
PAT-SM6 binding in FACS analysis and significant induction of
cytotoxicity (Fig. 3F), again demonstrating the specific induction of
cytotoxic effects by PAT-SM6.
Complement dependent cytotoxicity (CDC). Although
IgM antibodies are described to be excellent complement binders,
there is still conflicting data whether IgM antibodies can exert
cytotoxic effects by complement dependent cytotoxicity. We
therefore determined the capability of PAT-SM6 to bind and
activate complement. PAT-SM6 showed clear, but moderate
binding to C1q in an ELISA format compared to an unspecific
IgM isotype control. However, the IgG antibody Rituximab
serving as a positive control, displayed a stronger C1q binding
capacity (Fig. 4A), which correlates with superior C1q binding
properties of IgG antibodies in general.
To assess complement binding in a living cell system, PAT-
SM6-mediated deposition of C1q on the surface of OPM-2 cells
was assessed by FACS using human C1q and corresponding
antibodies. C1q deposition was clearly improved with the addition
of PAT-SM6 compared to cells treated with the isotype control
(Fig. 4B).
In order to determine complement-dependent cytotoxicity,
OPM-2 cells were co-incubated with various concentrations of
PAT-SM6 and human complement for 2 h, followed by the
measurement of lysed cells. PAT-SM6 treated cells showed a dose-
dependent cell death with a maximum of 40% lysed cells. Due to
the lack of CD20 expression in OPM-2 cells, Rituximab in the
same concentrations displayed no specific activity (Fig. 4C).
Finally, CDC activity was validated in primary MM cells
(n = 10). PAT-SM6 induced significant CDC with a rate of
20.9% (range 6.9–35%) vs. 11.4% (range 3.6–30%)(Fig. 4D).
Antibody-dependent cellular cytotoxicity (ADCC). While
there is good evidence that some therapeutic IgG antibodies
mediate antitumoural cytotoxicity via ADCC [5,20] the role of
Figure 4. PAT-SM6 binds to C1q and mediates complement deposition and activation on MM cell lines and patients material. A,
Sandwich ELISA: For C1q binding analysis, plates were coated with PAT-SM6 or controls (isotype or Rituximab). After blocking, plates were incubated
with human C1q followed by sheep anti human C1q-HRP. PAT-SM6 showed clear but moderate binding to C1q compared to the isotype control.
Rituximab displayed a stronger C1q binding capacity. B, PAT-SM6 mediated deposition of C1q on the surface of OPM-2 cells assessed by using human
C1q and detecting antibodies in FACS. C1q deposition was clearly improved with PAT-SM6 compared to cells without antibody treatment or isotype
control. C, CDC activity was determined using the alamar blue assay. OPM-2 cells were incubated with human complement (huC), PAT-SM6 or
controls for 2 hours followed by alamar blue solution and the amount of lysed cells was analysed with a fluorescence reader. A dose dependent
killing kinetic was observed. D, CD138-purified primary MM cells at primary diagnosis (n = 8, dots) or relapse (n = 2, rectangle) were incubated with
human complement, PAT-SM6 or controls (isotype, Rituximab) for 2 h and the amount of lysed was assessed by FACS (Propidium iodide/LDS75). In
the PAT-SM6 treated samples a moderate killing was observed, whereas Rituximab showed no significant cytotoxicity.
doi:10.1371/journal.pone.0063414.g004
IgM Antibody Induced Cell Death in MM
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ADCC in the cytotoxic properties of IgM antibodies is rather
unclear. We therefore analysed the ADCC activity of PAT-SM6 in
CFSE labelled target cells (OPM-2), PBMCs or purified natural
killer (NK) cells as effectors in a FACS-based assay. No specific
cell-mediated lysis of those target cells was observed (Figure S2).
To investigate putative immunomodulatory effects of IgM
antibodies, we investigated CD69 and CD25 expression on
effector subsets (T-, B- and NK cells) as surrogate markers for
an early activation phenotype or as a marker indicating inhibition
of immune effector cells. Whereas T- and B-cells showed no
significant expression changes, we confirmed findings by Pricop
and colleagues showing that unrelated polyclonal human IgM can
inhibit NK cell activation [21]. In contrast to human polyclonal
IgM, the monoclonal PAT-SM6 antibody did not change the
activation marker CD69 on NK cells indicating diverse biological
features of human monoclonal IgMs (Figure S3).
Discussion
Although novel therapeutic agents, such as thalidomide,
lenalidomide and the proteasome inhibitor bortezomib have
advanced treatment options for MM patients resulting in
prolonged survival times [22,23], MM nevertheless still remains
largely incurable and patients tend to relapse even after highly
intensified treatment approaches [23].
While antibody-based therapies are widely employed in
hematological malignancies, they have not yet entered standard
treatment in MM. This may be due, at least in part, to the lack of
optimal targets. However, several novel mAbs have been
developed during the last years, including monoclonal IgG
antibodies or related immune conjugates that specifically target
CD38, CS1, CD40, CD74, CD70, HM1.24, interleukin-6 and b2-
microglobulin (b2M) [8]. A panel of these IgG formatted
antibodies are currently evaluated in phase I to III studies [7].
Most of the initial observations in MM suggest that these mAbs
given as mono-therapy have limited antitumor activity; however, a
combination approach with other anti-myeloma agents may be a
promising new treatment strategy in myeloma.
We here show that the IgM antibody PAT-SM6 targets the heat
shock protein GRP78, which is stably and consistently expressed
on the surface of primary multiple myeloma cells from patients
with de novo MM, but also from patients with multiple relapses.
Binding of PAT-SM6 to the surface of MM cells results in the
induction of apoptosis and CDC, but not ADCC, demonstrating
that a fully human IgM antibody can specifically target and
eliminate malignant plasma cells.
Natural IgM antibodies are produced from germ line immuno-
globulin genes with few, if any, mutations. As a consequence of the
low mutation frequency, natural IgMs have low binding affinity
and a restricted binding repertoire. However, the multi-valency of
the pentameric structure creates high avidity and oligo-reactivity
to conserved structures (e.g. carbohydrates, phospholipids, nucleic
acids, and heat shock proteins), which makes them promising
therapeutic candidates. A single IgM antibody is able to bind
multiple copies of its specific target on a tumour cell, leading to
effective cross-linking of the targets and efficient induction of cell
death.
Several monoclonal IgM antibodies have been developed as
therapeutic agents and are administered in clinical trials where
evidence of efficacy was gathered [24–27]. Despite the growing
interest and clinical promise, however, IgM antibodies have so far
failed to gain widespread commercial interest as these antibodies
are considered to be difficult to handle in terms of production and
purification. Due to the large size and the extensively glycosylated
nature of these proteins, the production of sufficient quantities of
functionally active recombinant IgMs is indeed challenging.
However, over the last years, the availability of human therapeutic
IgM in GMP-grade is becoming more feasible due to the
implementation of recombinant expression systems like Per.C6H
[28] and successful increase in fermentation scale [16] making
IgM generation economically competitive to IgG antibodies. The
Per.C6H cell derived IgM antibody PAT-SM6 proved to be safe in
toxicity, toxicokinetics, and immunogenicity studies in cynomolgus
monkeys, showing no adverse reactions. Moreover, data generated
in humans from a phase I study in patients with recurrent in-
transit cutaneous melanoma, demonstrated a good safety profile
without any reported serious adverse events. In post-treatment
biopsies it could be demonstrated that the melanoma cells are
indeed reached and targeted by this IgM antibody in vivo (data not
shown).
The results of our study suggest that the induction of
programmed cell death (PCD) is the major effector mechanism
of cell death in MM cells targeted by PAT-SM6. This finding is in
line with previous observations in epithelial cancer types. The
induction of apoptotic processes is a common feature of natural
IgM antibodies as part of the immunosurveillance mechanisms
against malignant cells [17]. PAT-SM6 also activates CDC in MM
cells by recruiting the complement factor C1q. Compared to the
induction of programmed cell death, complement dependent
cytotoxicity appears to be moderate, but may represent an additive
effect to the main effector mechanism. A possible explanation for
this moderate CDC activity of PAT-SM6 could be that
pentameric natural human antibodies, which can pass epithelial
barriers via the polymeric immunoglobulin receptor, try to avoid
damage to healthy tissues, e.g. by complement activation in the
intestine or the lungs [29]. PAT-SM6, however, does not induce
ADCC, in line with previously reported results of other IgM
antibodies [30]. Thus, a combination therapy of PAT-SM6 with
other anti-myeloma agents that induce ADCC, e.g. lenalidomide
or proteasome inhibitors, might exert synergistic effects in
inducing myeloma cell death [7].
We have previously shown that PAT-SM6 cross-reacts with
both cell surface expressed GRP78 and oxidized LDL thereby
inducing apoptosis in target cells [9,12,13]. GRP78 belongs to the
group of heat shock proteins (HSP) which have attracted attention
in MM in recent years, as their dysregulation may contribute to
the pathogenesis of MM [31–33]. HSPs are ubiquitous molecular
chaperones involved in posttranslational folding, stabilization,
maturation and activation of various proteins that are essential
mediators of signal transduction and cell cycle progression.
Environmental and other stress inducing stimuli lead to an
increased intracellular synthesis of HSPs [34]. At high levels, the
chaperones protect the cell against ER stress-induced apoptosis
and maintain cell viability after exposure to stress-inducing
conditions [35]. The result is a complex network of regulators
and protective mechanisms, which help the cell to respond to stress
stimuli [36] and to prevent cellular degradation processes, induced
by apoptosis and autophagocytosis. HSPs are normally cytoplas-
mic proteins, but under diverse pathological conditions they are
over-expressed and found on the surface of cells where they may
serve as cell-surface signalling receptors [37]. As in malignant cells
hypoxia and glucose deprivation is considered to be a permanent
matter of stress, it is not surprising that tumour cells up-regulate
HSPs to prevent cellular and molecular damage [11,38,39].
GRP78 (BIP, HSPA5) is a member of the HSP70 family and
cell-surface-located GRP78 is found in a variety of malignant
tumours including breast, lung, gastric, hepatocellular and prostate
cancers. The expression correlates with tumour progression,
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metastasis formation and drug resistance [38]. Of note, natural
antibodies to GRP78 were found in the serum of prostate cancer
patients, which further points to the antigenic property of surface
GRP78 [40,41].
In summary, we show that the PAT-SM6 target GRP78 is
widely expressed on the surface of primary MM cells, but not on
normal plasma cells or other hematopoietic or non-hematopoietic
cells. Binding of PAT-SM6 to the surface of MM cells, results in
the effective induction of apoptosis and CDC, thus making this
natural IgM antibody an attractive novel agent in the armamen-
tarium of treatments for MM patients. As a fully human antibody,
PAT-SM6 may reduce the risk of host-protective immune
responses. The favourable toxicity profiles of PAT-SM6 combined
with its high avidity binding to the target GRP78 and its
interaction with host immune effectors form the basis for a phase I
multi-dose escalating study in patients with relapsed multiple
myeloma. This trial commenced at the end of 2012 and is
currently ongoing.
Supporting Information
Figure S1 PAT-SM6 displays a membrane staining in
cytospin preparations of patients MM cells. CD138-
purified primary MM cells were centrifuged by cytospin, fixed
and permeabilised with acetone and incubated with PAT-SM6 or
controls (isotype, anti CD138). Detection followed with corre-
sponding HRP-conjugated secondary antibodies. PAT-SM6
showed binding to CD138 purified primary MM cells specifically.
As non-malignant control, plasma cells were obtained from 50 mL
peripheral blood from healthy volunteers by Ficoll gradient
centrifugation and subsequently CD138 isolation using magnetic
beads. CD138 isolated cells from a healthy donor showed no
binding when incubated with PAT-SM6. Images were captured
using a Leica DM BL microscope, the Leica ICC HD digital
camera and the Leica LAS EZ V2.1.0 software.
(TIF)
Figure S2 PAT-SM6 does not induce ADCC on OPM-2
cells. CFSE labelled MM cells were incubated with PAT-SM6
(25 mg/mL or 50 mg/mL) or controls (polyclonal IgM) and PBMC
from healthy donors in an effector to target ratio of 25:1 in RPMI
supplemented with 1% human serum. 4 or 24 h after incubation
cells were stained with 7-AAD for cell death determination and
analysed by FACS. 7-AAD/CFSE double positive cells were set as
MM cells killed by ADCC.
(TIF)
Figure S3 In contrast to polyclonal IgM PAT-SM6 shows
no impairment in NK cell activation assessed by CD69
expression. OPM-2 myeloma cells were incubated with PAT-
SM6 or unrelated polyclonal IgM (Chrompure, Dianova,
Hamburg, Germany) for 15 min on ice followed by centrifugation
and dismissing of supernatant to relieve unbound antibody. Cells
were transferred into a 24 well plate (flat bottom) and co-incubated
with PBMC from a healthy donor in an effector to target ratio of
10:1 for 0 (black histogram) and 20 hours (blue histogram). NK cell
activation was determined using CD56, CD3 and CD69
fluorescent conjugated antibodies (BD, Heidelberg, Germany).
Whereas polyclonal IgM inhibits NK cell activation PAT-SM6
showed no inhibitory activity.
(TIF)
Acknowledgments
The authors thank Miriam Eckstein and Nadine Vornberger for excellent
technical assistance.
Author Contributions
Conceived and designed the experiments: LR MST SB. Performed the
experiments: LR JD CM. Analyzed the data: LR JD FH AR HEMCMST
SB. Contributed reagents/materials/analysis tools: JD MC. Wrote the
paper: LR FH AR HE MST SB.
References
1. Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364: 1046–
1060.
2. Chanan-Khan AA, Giralt S (2010) Importance of achieving a complete response
in multiple myeloma, and the impact of novel agents. J Clin Oncol 28: 2612–
2624.
3. Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for
cancer immunotherapy. Lancet 373: 1033–1040.
4. Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC (2011)
Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol
154: 745–754.
5. Tai YT, Dillon M, Song W, Leiba M, Li XF, et al. (2008) Anti-CS1 humanized
monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces
antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112:
1329–1337.
6. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, et al. (2011)
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces
killing of multiple myeloma and other hematological tumors. J Immunol 186:
1840–1848.
7. van de Donk NW, Kamps S, Mutis T, Lokhorst HM (2012) Monoclonal
antibody-based therapy as a new treatment strategy in multiple myeloma.
Leukemia 26: 199–213.
8. Yang J, Yi Q (2011) Therapeutic monoclonal antibodies for multiple myeloma:
an update and future perspectives. Am J Blood Res 1: 22–33.
9. Rauschert N, Brandlein S, Holzinger E, Hensel F, Muller-Hermelink HK, et al.
(2008) A new tumor-specific variant of GRP78 as target for antibody-based
therapy. Lab Invest 88: 375–386.
10. Zhang Y, Liu R, Ni M, Gill P, Lee AS (2010) Cell surface relocalization of the
endoplasmic reticulum chaperone and unfolded protein response regulator
GRP78/BiP. J Biol Chem 285: 15065–15075.
11. Lee AS (2007) GRP78 induction in cancer: therapeutic and prognostic
implications. Cancer Res 67: 3496–3499.
12. Pohle T, Brandlein S, Ruoff N, Muller-Hermelink HK, Vollmers HP (2004)
Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid
accumulation. Cancer Res 64: 3900–3906.
13. Brandlein S, Rauschert N, Rasche L, Dreykluft A, Hensel F, et al. (2007) The
human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized
low-density lipoprotein. Mol Cancer Ther 6: 326–333.
14. Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, Henze C, Loffler D, et al.
(2004) Interleukin-6-dependent gene expression profiles in multiple myeloma
INA-6 cells reveal a Bcl-2 family-independent survival pathway closely
associated with Stat3 activation. Blood 103: 242–251.
15. Stuhmer T, Arts J, Chatterjee M, Borawski J, Wolff A, et al. (2010) Preclinical
anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585.
Br J Haematol 149: 529–536.
16. Valasek C. Cole J, Hensel F, Ye P, Conner MA, et al. (2011) Production and
Purification of a PER.C6-Expressed IgM Antibody Therapeutic. BioProcess
International 9: 28–37.
17. Brandlein S, Pohle T, Ruoff N, Wozniak E, Muller-Hermelink HK, et al. (2003)
Natural IgM antibodies and immunosurveillance mechanisms against epithelial
cancer cells in humans. Cancer Res 63: 7995–8005.
18. Mashima T, Naito M, Kataoka S, Kawai H, Tsuruo T (1995) Aspartate-based
inhibitor of interleukin-1 beta-converting enzyme prevents antitumor agent-
induced apoptosis in human myeloid leukemia U937 cells. Biochem Biophys Res
Commun 209: 907–915.
19. Gerritsen AF, Bosch M, de Weers M, de Winkel JG, Parren PW (2010) High
throughput screening for antibody induced complement-dependent cytotoxicity
in early antibody discovery using homogeneous macroconfocal fluorescence
imaging. J Immunol Methods 352: 140–146.
20. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, et al. (2010) Increasing
the efficacy of CD20 antibody therapy through the engineering of a new type II
anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-
cell cytotoxicity. Blood 115: 4393–4402.
21. Pricop L, Rabinowich H, Morel PA, Sulica A, Whiteside TL, et al. (1993)
Characterization of the Fc mu receptor on human natural killer cells. Interaction
with its physiologic ligand, human normal IgM, specificity of binding, and
functional effects. J Immunol 151: 3018–3029.
IgM Antibody Induced Cell Death in MM
PLOS ONE | www.plosone.org 10 May 2013 | Volume 8 | Issue 5 | e63414
22. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. (2008)
Improved survival in multiple myeloma and the impact of novel therapies. Blood
111: 2516–2520.
23. Anderson KC (2011) New insights into therapeutic targets in myeloma.
Hematology Am Soc Hematol Educ Program 2011: 184–190.
24. Irie RF, Ollila DW, O’Day S, Morton DL (2004) Phase I pilot clinical trial of
human IgM monoclonal antibody to ganglioside GM3 in patients with
metastatic melanoma. Cancer Immunol Immunother 53: 110–117.
25. Mordoh J, Silva C, Albarellos M, Bravo AI, Kairiyama C (1995) Phase I clinical
trial in cancer patients of a new monoclonal antibody FC-2.15 reacting with
tumor proliferating cells. J Immunother Emphasis Tumor Immunol 17: 151–
160.
26. Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, et al. (2007) A
phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as
secondary therapy for steroid-resistant acute graft-versus-host disease. Blood
109: 2657–2662.
27. Derkx B, Wittes J, McCloskey R (1999) Randomized, placebo-controlled trial of
HA-1A, a human monoclonal antibody to endotoxin, in children with
meningococcal septic shock. European Pediatric Meningococcal Septic Shock
Trial Study Group. Clin Infect Dis 28: 770–777.
28. Tchoudakova A, Hensel F, Murillo A, Eng B, Foley M, et al. (2009) High level
expression of functional human IgMs in human PER.C6 cells. MAbs 1: 163–
171.
29. Randall TD, Parkhouse RM, Corley RB (1992) J chain synthesis and secretion of
hexameric IgM is differentially regulated by lipopolysaccharide and interleukin
5. Proc Natl Acad Sci U S A 89: 962–966.
30. Sawada R, Sun SM, Wu X, Hong F, Ragupathi G, et al. (2011) Human
monoclonal antibodies to sialyl-Lewisa (CA19.9) with potent CDC, ADCC, and
antitumor activity. Clin Cancer Res 17: 1024–1032.
31. Chatterjee M, Jain S, Stuhmer T, Andrulis M, Ungethum U, et al. (2007)
STAT3 and MAPK signaling maintain overexpression of heat shock proteins
90alpha and beta in multiple myeloma cells, which critically contribute to
tumor-cell survival. Blood 109: 720–728.
32. Davenport EL, Moore HE, Dunlop AS, Sharp SY, Workman P, et al. (2007)
Heat shock protein inhibition is associated with activation of the unfolded
protein response pathway in myeloma plasma cells. Blood 110: 2641–2649.
33. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, et al. (2006)
Antimyeloma activity of heat shock protein-90 inhibition. Blood 107: 1092–
1100.
34. Lee AS (2001) The glucose-regulated proteins: stress induction and clinical
applications. Trends Biochem Sci 26: 504–510.
35. Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, et al. (2007) Glucose-
regulated protein GRP78 is up-regulated in prostate cancer and correlates with
recurrence and survival. Hum Pathol 38: 1547–1552.
36. Hendershot LM (2004) The ER function BiP is a master regulator of ER
function. Mt Sinai J Med 71: 289–297.
37. Misra UK, Gonzalez-Gronow M, Gawdi G, Wang F, Pizzo SV (2004) A novel
receptor function for the heat shock protein Grp78: silencing of Grp78 gene
expression attenuates alpha2M*-induced signalling. Cell Signal 16: 929–938.
38. Li J, Lee AS (2006) Stress induction of GRP78/BiP and its role in cancer. Curr
Mol Med 6: 45–54.
39. Feldman DE, Chauhan V, Koong AC (2005) The unfolded protein response: a
novel component of the hypoxic stress response in tumors. Mol Cancer Res 3:
597–605.
40. Arap MA, Lahdenranta J, Mintz PJ, Hajitou A, Sarkis AS, et al. (2004) Cell
surface expression of the stress response chaperone GRP78 enables tumor
targeting by circulating ligands. Cancer Cell 6: 275–284.
41. Gonzalez-Gronow M, Cuchacovich M, Llanos C, Urzua C, Gawdi G, et al.
(2006) Prostate cancer cell proliferation in vitro is modulated by antibodies
against glucose-regulated protein 78 isolated from patient serum. Cancer Res 66:
11424–11431.
IgM Antibody Induced Cell Death in MM
PLOS ONE | www.plosone.org 11 May 2013 | Volume 8 | Issue 5 | e63414
